Last reviewed · How we verify

Baxdela — Competitive Intelligence Brief

Baxdela (DELAFLOXACIN) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoroquinolone Antibacterial. Area: Infectious Disease.

marketed Fluoroquinolone Antibacterial Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Baxdela (DELAFLOXACIN) — Melinta. Baxdela works by blocking bacterial enzymes that replicate DNA.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Baxdela TARGET DELAFLOXACIN Melinta marketed Fluoroquinolone Antibacterial 2017-01-01
Levaquin levofloxacin Generic (originally Daiichi Sankyo/J&J) marketed Fluoroquinolone Antibacterial [EPC] CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2 1996-12-20
Levaquin Levofloxacin Santen marketed Fluoroquinolone Antibacterial [EPC] Multidrug and toxin extrusion protein 1 1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fluoroquinolone Antibacterial class)

  1. Melinta · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Baxdela — Competitive Intelligence Brief. https://druglandscape.com/ci/delafloxacin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing